FDA grants Ivermectin compassionate special permit to another hospital | Inquirer News
Close  

FDA grants Ivermectin compassionate special permit to another hospital

/ 09:25 AM April 16, 2021

MANILA, Philippines — Another hospital has been granted a compassionate special permit (CSP) to use Ivermectin in the treatment of COVID-19, Food and Drug Administration (FDA) Director-General Eric Domingo disclosed Friday.

Domingo did not disclose which hospital was given the second CSP for Ivermectin. He merely said it is a private hospital.

ADVERTISEMENT

“Two hospitals na actually ‘yung nag-apply sa atin and have been given CSP,” Domingo said in an interview with ABS-CBN News Channel’s Headstart.

Domingo also confirmed the information to INQUIRER.net in a text message.

FEATURED STORIES

On April 8, FDA announced it has granted a hospital, the name of which was not disclosed due to privacy issues, a CSP for the use of Ivermectin to counter COVID-19.

The FDA gives CSP to allow limited use of investigational drugs or unregistered drugs.

KGA

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: compassionate special permit , Coronavirus, COVID-19, CSP, FDA, Health, hospital, Ivermectin, pandemic, SARS-CoV-2, Virus
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2021 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.